New cocoa flavanol study provides evidence for cardiovascular health

20 February 2006

While a growing number of studies has shown a link between flavanol-rich cocoa and cardiovascular health, scientists have now substantiated a causal relationship between specific compounds present in cocoa and cardiovascular health. Published last month in the Proceedings of the National Academy of Sciences of the USA (PNAS), this new study identifies the flavanol (-)epicatechin, as one of the bioactive nutrients in cocoa that can improve the ability of blood vessels to relax.

An international team of scientists from the University of Dusseldorf, Germany; the University of California, Davis; confectionery giant Mars Inc; and the Harvard Medical School conducted a series of studies examining the role of specific cocoa flavanols in cardiovascular health.

"Applying accepted causality criteria and gold standard methodologies, we have been able to advance our understanding of the relationship between the intake of certain flavanols present in cocoa, their absorption into the circulation, and their effects on cardiovascular function," said lead author Hagen Schroeter, faculty member at the University of California, adding: "this study established direct evidence for the effect of the flavanol (-)epicatechin as a mediator of blood vessel relaxation."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight